| Phase 4 |
| NCT07788456 |
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed… |
ITP - Immune Thrombocytopenia |
Recruiting |
2026-08-26 |
| NCT04518475 |
Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune… |
Primary Immune Thrombocytopenia (ITP) |
Recruiting |
2026-04-29 |
| NCT07406139 |
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） |
Hemophilia |
Recruiting |
2026-02-12 |
| NCT05849740 |
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined… |
Acquired Hemophilia |
Recruiting |
2025-08-05 |
| NCT05888870 |
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults… |
Hemophilia A With Inhibitor |
Recruiting |
2025-02-24 |
| Phase 3 |
| NCT06744504 |
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… |
AML |
Recruiting |
2026-08-07 |
| NCT07132684 |
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… |
AML, Adult |
Recruiting |
2026-03-02 |
| NCT07152041 |
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol |
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) |
Recruiting |
2025-09-03 |
| NCT07723911 |
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL |
Precursor B-cell Acute Lymphoblastic Leukemia |
Not Yet Recruiting |
2026-07-23 |
| NCT07686965 |
Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell… |
Acute Myeloid Leukemia (AML) |
Not Yet Recruiting |
2026-07-07 |
| NCT07588945 |
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT |
Transplant-Related Disorder |
Not Yet Recruiting |
2026-05-15 |
| NCT07539818 |
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML |
AML |
Not Yet Recruiting |
2026-04-20 |
| NCT07407140 |
VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated… |
AML, Adult |
Not Yet Recruiting |
2026-03-25 |
| NCT03021330 |
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML |
AML |
Active, Not Recruiting |
2025-05-30 |
| NCT06888479 |
Optimal Timing of Hepatitis B Vaccination After Transplants |
Transplant-Related Disorder |
Not Yet Recruiting |
2025-03-21 |
| NCT06613035 |
Twice-per-weekSelinexor, 2 Days Melphalan |
Acute Myeloid Leukemia |
Not Yet Recruiting |
2024-09-25 |
| Phase 2/3 |
| NCT06764238 |
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol |
Acute Lymphoblastic Leukemia ALL |
Recruiting |
2026-07-23 |
| NCT06855810 |
Newly-diagnosed Pediatric T-cell ALL Protocol |
Acute Lymphoblastic Leukemia |
Recruiting |
2025-08-26 |
| NCT06882057 |
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol |
Acute Lymphoblastic Leukemia ALL |
Recruiting |
2025-08-26 |
| NCT07278908 |
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune… |
ITP - Immune Thrombocytopenia |
Not Yet Recruiting |
2025-12-12 |
| NCT05356169 |
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia |
Acute Myeloid Leukemia |
Active, Not Recruiting |
2025-05-30 |
| Phase 2 |
| NCT07115654 |
BCMA/CD3 BsAb Therapy for POEMS Syndrome |
POEMS Syndrome |
Recruiting |
2026-09-29 |
| NCT07652905 |
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia |
Plasma Cell Leukemia (PCL) |
Recruiting |
2026-09-18 |
| NCT07585760 |
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment |
Multiple Myeloma (MM) |
Recruiting |
2026-09-17 |
| NCT07409454 |
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly… |
Multiple Myeloma |
Recruiting |
2026-08-07 |